The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...

EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome: Boston Monday, January 27, 2025, 11:00 Hrs [IST] X4 Pharmaceuticals, a comp ...

Submission supported by positive results from global, Phase 3 4WHIM clinical trial;U.S. regulatory approval in WHIM syndrome granted in ...

Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.Continued ...

Standard induction therapy with lenalidomide, bortezomib, and dexamethasone did not overcome inferior outcomes in patients ...

Study identifies NMLR as a predictor of 5-year mortality in COPD patients, paving the way for personalised care and improved survival outcomes.

T lymphocytes play a pivotal role in resolving hepatitis B virus infection. This study aimed to investigate the dynamics of peripheral blood T ...

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...

In February 2024, the FDA granted breakthrough therapy designation to NVL-520 as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer (NSCLC) who received prior treatment ...

The following is a summary of “Neutrophil-to-lymphocyte ratio as a predictor for early mortality in older patients requiring hemodialysis; insights for hemodialysis access planning,” published in the ...

2005). Blood samples were collected and tested within 24 h after hospital admission for all participating patients. Lymphocyte counts, as a marker of routine blood tests were measured by flow ...

Current immunotherapies targeting cholangiocarcinoma have predominantly focused on T lymphocytes within the tumor microenvironment, and new immunotherapies have yielded unsatisfactory results in ...